登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，7月30日，ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-08-18

  • ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
    Neeltje van Doremalen, Teresa Lambe, […]Vincent J. Munster
    Nature (2020)

    Abstract
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 20191,2 and is responsible for the COVID-19 pandemic3. Vaccines are an essential countermeasure urgently needed to control the pandemic4. Here, we show that the adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2, is immunogenic in mice, eliciting a robust humoral and cell-mediated response. This response was predominantly Th1, as demonstrated by IgG subclass and cytokine expression profiling. Vaccination with ChAdOx1 nCoV-19 (prime-only and prime-boost regimen) induced a balanced Th1/Th2 humoral and cellular immune response in rhesus macaques. We observed a significantly reduced viral load in bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated animals. However, there was no difference in nasal shedding between vaccinated and control animals. Importantly, no evidence of immune-enhanced disease following viral challenge in vaccinated animals was observed. Safety, immunogenicity and efficacy of ChAdOx1 nCoV-19 against symptomatic PCR-positive COVID-19 disease will now be assessed in randomised controlled human clinical trials.

  • 原文来源：https://www.nature.com/articles/s41586-020-2608-y
79浏览量
原文链接
相关报告

  • 《7月30日_ChAdOx1 nCoV-19疫苗可预防恒河猴的SARS-CoV-2肺炎》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-08-18
    • Nature于7月30日发表了美国国立卫生研究院和英国牛津大学的研究文章“ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques”。研究人员证明了编码SARS-CoV-2的刺突蛋白腺病毒载体疫苗ChAdOx1 nCoV-19具有免疫原性，可引起小鼠体内强烈的体液和细胞介导反应。IgG亚类和细胞因子表达谱显示，这种反应主要是Th1体液免疫和细胞免疫反应。接种ChAdOx1 nCoV-19疫苗（仅初次免疫和初免-加强免疫）可诱导恒河猴体内发生平衡的Th1/Th2体液免疫和细胞免疫反应。与对照组相比，研究人员观察到接种了SARS-CoV-2疫苗的恒河猴的支气管肺泡灌洗液和下呼吸道组织中的病毒载量显著降低，接种后的动物没有肺炎症状。然而，接种疫苗的动物和对照组的动物在鼻脱落方面没有差异。重要的是，在接种疫苗的动物中没有观察到病毒攻击后免疫增强疾病的证据。ChAdOx1 nCoV-19对有症状的PCR阳性COVID-19的安全性、免疫原性和有效性将通过随机对照人类临床试验进行评估。 4.附件： 原文链接：https://www.nature.com/articles/s41586-020-2608-y
    134浏览量
    原文链接

  • 《Nature，12月17日，Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-01-29
    • Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses Jordan R. Barrett, Sandra Belij-Rammerstorfer, […]the Oxford COVID Vaccine Trial Group Nature Medicine (2020) Abstract More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral spike protein may correlate with protection, additional antibody functions may also be important in preventing infection. Previously, we reported early immunogenicity and safety outcomes of a viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222), in a single-blinded phase 1/2 randomized controlled trial of healthy adults aged 18–55 years (NCT04324606). Now we describe safety and exploratory humoral and cellular immunogenicity of the vaccine, from subgroups of volunteers in that trial, who were subsequently allocated to receive a homologous full-dose (SD/SD D56; n = 20) or half-dose (SD/LD D56; n = 32) ChAdOx1 booster vaccine 56 d following prime vaccination. Previously reported immunogenicity data from the open-label 28-d interval prime-boost group (SD/SD D28; n = 10) are also presented to facilitate comparison. Additionally, we describe volunteers boosted with the comparator vaccine (MenACWY; n = 10). In this interim report, we demonstrate that a booster dose of ChAdOx1 nCoV-19 is safe and better tolerated than priming doses. Using a systems serology approach we also demonstrate that anti-spike neutralizing antibody titers, as well as Fc-mediated functional antibody responses, including antibody-dependent neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation, are substantially enhanced by a booster dose of vaccine. A booster dose of vaccine induced stronger antibody responses than a dose-sparing half-dose boost, although the magnitude of T cell responses did not increase with either boost dose. These data support the two-dose vaccine regime that is now being evaluated in phase 3 clinical trials.
    60浏览量
    原文链接